EyePoint Doses First Patients in Pivotal Phase 3 Trials for DURAVYU™ in Diabetic Macular Edema

summarizeSummary

EyePoint, Inc. announced the dosing of the first patients in its two global Phase 3 clinical trials (COMO and CAPRI) for DURAVYU™ in diabetic macular edema (DME), marking a significant advancement in its lead product candidate's development.

check_boxKey Events

• Phase 3 DME Trials Initiated

  EyePoint announced the dosing of the first patients in its global Phase 3 COMO and CAPRI clinical trials for DURAVYU™ (vorolanib intravitreal insert) for diabetic macular edema (DME).

• DURAVYU's Differentiated Profile

  DURAVYU is highlighted as the only tyrosine kinase inhibitor (TKI) in Phase 3 for DME, offering a novel multi-mechanism of action and sustained delivery for at least six months.

• Regulatory Alignment

  The Phase 3 program design, informed by positive Phase 2 results, has alignment with both the U.S. FDA and European Medicines Agency (EMA), following an established non-inferiority regulatory pathway.

• Anticipated Data Timeline

  Topline data from the DME pivotal program is expected in the second half of 2027.

auto_awesomeAnalysis

This 8-K reports a critical milestone for EyePoint, Inc. as it initiates Phase 3 clinical trials for DURAVYU™ in diabetic macular edema (DME), a multi-billion dollar market. The company highlights DURAVYU's novel multi-mechanism of action and sustained-release delivery, positioning it as a potentially differentiated treatment. The trial design, aligned with FDA and EMA, aims for non-inferiority against standard of care, de-risking the regulatory pathway. This progress, alongside ongoing Phase 3 trials for wet AMD and a strong cash position into Q4 2027 (as previously reported), underscores the company's advancement in its pipeline and commitment to addressing serious retinal diseases. Investors should monitor the progress of these trials, with topline data for DME anticipated in 2H 2027.